MX2020005921A - Formulaciones y metodos para el suministro vaginal de antiprogestinas. - Google Patents

Formulaciones y metodos para el suministro vaginal de antiprogestinas.

Info

Publication number
MX2020005921A
MX2020005921A MX2020005921A MX2020005921A MX2020005921A MX 2020005921 A MX2020005921 A MX 2020005921A MX 2020005921 A MX2020005921 A MX 2020005921A MX 2020005921 A MX2020005921 A MX 2020005921A MX 2020005921 A MX2020005921 A MX 2020005921A
Authority
MX
Mexico
Prior art keywords
antiprogestins
methods
vaginal delivery
formulations
vaginal
Prior art date
Application number
MX2020005921A
Other languages
English (en)
Inventor
Joseph S Podolski
Kuang Hsu
Original Assignee
Repros Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Repros Therapeutics Inc filed Critical Repros Therapeutics Inc
Publication of MX2020005921A publication Critical patent/MX2020005921A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Abstract

El objeto de la presente invención se refiere al campo de suministro vaginal de agentes farmacéuticamente activos. Las formas de realización de la presente invención revelan métodos para tratar una variedad de trastornos relacionados con la progesterona mediante la administración vaginal de una cápsula de pululano y una formulación de relleno que comprende una o varias antiprogestinas dispersas en una mezcla de palmitato de isopropilo o miristato de isopropilo y un polietilenglicol.
MX2020005921A 2014-05-05 2016-10-31 Formulaciones y metodos para el suministro vaginal de antiprogestinas. MX2020005921A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461988766P 2014-05-05 2014-05-05

Publications (1)

Publication Number Publication Date
MX2020005921A true MX2020005921A (es) 2020-08-20

Family

ID=54392846

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016014256A MX2016014256A (es) 2014-05-05 2015-04-22 Formulaciones y metodos para el suministro vaginal de antiprogestinas.
MX2020005921A MX2020005921A (es) 2014-05-05 2016-10-31 Formulaciones y metodos para el suministro vaginal de antiprogestinas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016014256A MX2016014256A (es) 2014-05-05 2015-04-22 Formulaciones y metodos para el suministro vaginal de antiprogestinas.

Country Status (10)

Country Link
US (3) US10064815B2 (es)
EP (1) EP3139908A4 (es)
JP (2) JP6591447B2 (es)
CN (2) CN111840246A (es)
AU (1) AU2015256473B2 (es)
CA (1) CA2948287A1 (es)
HK (1) HK1232125A1 (es)
IL (1) IL248621B (es)
MX (2) MX2016014256A (es)
WO (1) WO2015171319A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018189584A1 (en) * 2017-04-14 2018-10-18 Capsugel Belgium Nv Pullulan capsules
US10857151B1 (en) 2020-02-21 2020-12-08 Villya LLC Treatment of female genital schistosomiasis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982091B2 (en) * 2001-08-29 2006-01-03 Umd, Inc. Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy
US20050070516A1 (en) * 1997-10-28 2005-03-31 Vivus Inc. As-needed administration of an androgenic agent to enhance female desire and responsiveness
US7417013B2 (en) 2002-05-01 2008-08-26 Mcneil-Ppc, Inc. Warming and nonirritating lubricant compositions and method of comparing irritation
EP1593376A1 (en) * 2004-05-04 2005-11-09 Warner-Lambert Company LLC Improved pullulan capsules
WO2007103510A2 (en) * 2006-03-08 2007-09-13 Danco Laboratories Llc Methods, dosing regimens & medications using anti-progestational agents for the treatment of disorders
EP2144601A4 (en) * 2007-04-05 2012-10-10 Univ Kansas RAPID DISSOLVING PHARMACEUTICAL COMPOSITIONS COMPRISING PULLULANE
JP2011502172A (ja) * 2007-11-02 2011-01-20 アクルックス・ディ・ディ・エス・プロプライエタリー・リミテッド ホルモンおよびステロイド用の経皮送達システム
KR20130009990A (ko) * 2010-03-22 2013-01-24 레프로스 쎄라피우틱스 아이엔씨. 항프로게스틴의 비독성 전달을 위한 조성물들과 그 방법들
UA113283C2 (xx) * 2010-12-23 2017-01-10 19-норстероїди і їх застосування для лікування прогестеронзалежних станів
ES2885523T3 (es) * 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
SG10201704858PA (en) * 2012-05-31 2017-07-28 Repros Therapeutics Inc Formulations and methods for vaginal delivery of antiprogestins

Also Published As

Publication number Publication date
US10555900B2 (en) 2020-02-11
CA2948287A1 (en) 2015-11-12
US10064815B2 (en) 2018-09-04
WO2015171319A1 (en) 2015-11-12
HK1232125A1 (zh) 2018-01-05
CN106232107B (zh) 2020-06-05
US20170181965A1 (en) 2017-06-29
JP6796693B2 (ja) 2020-12-09
AU2015256473A1 (en) 2016-11-17
EP3139908A4 (en) 2018-05-16
US20180325810A1 (en) 2018-11-15
JP6591447B2 (ja) 2019-10-16
IL248621A0 (en) 2017-01-31
AU2015256473B2 (en) 2018-07-12
MX2016014256A (es) 2017-02-06
JP2017514851A (ja) 2017-06-08
JP2019194271A (ja) 2019-11-07
IL248621B (en) 2020-09-30
EP3139908A1 (en) 2017-03-15
CN106232107A (zh) 2016-12-14
CN111840246A (zh) 2020-10-30
US20200222315A1 (en) 2020-07-16

Similar Documents

Publication Publication Date Title
MX2019003467A (es) Formulaciones y metodos para la administracion vaginal de antiprogestinas.
CL2019003433A1 (es) Composición farmacéutica oftálmica que comprende nanopartículas mucopenetrantes, cuyo núcleo comprende un agente activo farmacéutico seleccionado entre un inhibidor de receptor tirosina quinasa (rtk), o un inhibidor de la angiogénesis, y está recubierto con un polímero modificador de superficie; y uso para tratar un trastorno del ojo (divisional de solicitud cl 2956-2014).
MX2021006035A (es) Formulaciones cannabinoides estables.
CO2019000938A2 (es) Moduladores nmda espiro-lactam y métodos de uso de los mismos
CL2019000248A1 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
CL2019000247A1 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos.
CO2019000944A2 (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos
CO2019000941A2 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
MX2015015589A (es) Composiciones y metodos para el suministro de agentes activos hidrófobos.
CL2020000747A1 (es) Formulaciones de niraparib.
MX2014008284A (es) Formulacion de liberacion retardada para reducir la frecuencia de orinar y metodos de uso de esta.
NZ792518A (en) Formulations for administration of eflornithine
NZ718163A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
MX2022013450A (es) Formulaciones farmaceuticas.
MX2020005921A (es) Formulaciones y metodos para el suministro vaginal de antiprogestinas.
MX2017005163A (es) Composiciones de liberación prolongada de onapristona y métodos.
MX2018000800A (es) Formulaciones y tratamientos topicos.
MX2020003697A (es) Formulaciones farmaceuticas que comprenden un agonista del receptor opioide como ingredientes activos, metodos de fabricacion y usos terapeuticos de las mismas.
MX2018005876A (es) Regimen de dosificacion de plasminogeno para la cicatrizacion de heridas.
AR086252A1 (es) Formulacion topica que comprende dipropionato de beclometasona como ingrediente activo
MX2018008196A (es) Tratamiento para cancer de mama usando una combinacion de una formulacion liposomal cationica de taxano, una formulacion no liposomal de taxano y un agente activo adicional.
GR1008819B (el) Φαρμακευτικο σκευασμα που περιλαμβανει ατομοξετινη και μεθοδος παρασκευης αυτου
EA201500128A1 (ru) Педиатрические жидкие композиции для перорального введения, содержащие непадутант
TR201714726A1 (tr) Antikolinerjik bir etken madde içeren farmasötik formülasyon.
MX2019003229A (es) Formulaciones liquidas estables.